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The article Osimertinib as first-line therapy in advanced NSCLC: a profile of its use, written by Lesley J. Scott, was originally published Online First without open access. After publication in volume 34, issue 8, pages 351--357, AstraZeneca Pharmaceuticals LP requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AstraZeneca Pharmaceuticals LP. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.
